↓ Skip to main content

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

Overview of attention for article published in BMC Cancer, December 2013
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Published in
BMC Cancer, December 2013
DOI 10.1186/1471-2407-13-613
Pubmed ID
Authors

Masanori Noguchi, Fukuko Moriya, Shigetaka Suekane, Rei Ohnishi, Satoko Matsueda, Tetsuro Sasada, Akira Yamada, Kyogo Itoh

Abstract

Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Several surrogate markers for evaluation of cancer vaccine, including prostate-specific antigen doubling time (PSADT), are currently sought. The purpose of this study was to assess prospectively the PSA kinetics and immune responses, as well as the efficacy, safety, and biomarkers of personalized peptide vaccination (PPV) in progressive CRPC.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 51 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 23%
Researcher 8 15%
Student > Master 8 15%
Student > Bachelor 7 13%
Student > Doctoral Student 5 10%
Other 8 15%
Unknown 4 8%
Readers by discipline Count As %
Medicine and Dentistry 22 42%
Computer Science 4 8%
Immunology and Microbiology 4 8%
Agricultural and Biological Sciences 4 8%
Sports and Recreations 2 4%
Other 9 17%
Unknown 7 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2014.
All research outputs
#3,063,845
of 4,507,509 outputs
Outputs from BMC Cancer
#1,518
of 2,430 outputs
Outputs of similar age
#80,273
of 122,690 outputs
Outputs of similar age from BMC Cancer
#53
of 87 outputs
Altmetric has tracked 4,507,509 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,430 research outputs from this source. They receive a mean Attention Score of 2.4. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,690 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.